Anika Therapeutics (NASDAQ:ANIK – Get Free Report) will be releasing its earnings data before the market opens on Thursday, October 31st. Analysts expect Anika Therapeutics to post earnings of $0.30 per share for the quarter. Anika Therapeutics has set its FY 2024 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.
Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.24). Anika Therapeutics had a negative net margin of 44.45% and a positive return on equity of 0.94%. The company had revenue of $41.92 million during the quarter, compared to analyst estimates of $39.90 million. During the same period last year, the firm earned ($0.06) EPS. On average, analysts expect Anika Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Anika Therapeutics Price Performance
ANIK opened at $24.54 on Thursday. Anika Therapeutics has a 1 year low of $18.08 and a 1 year high of $29.11. The stock has a market cap of $357.96 million, a P/E ratio of -4.67 and a beta of 0.83. The firm has a fifty day moving average price of $25.09 and a 200 day moving average price of $25.79.
Analyst Ratings Changes
Read Our Latest Analysis on Anika Therapeutics
Anika Therapeutics Company Profile
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
Recommended Stories
- Five stocks we like better than Anika Therapeutics
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Are Penny Stocks a Good Fit for Your Portfolio?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.